Equities research analysts at Aegis increased their price objective on shares of Inovio Pharmaceuticals (NYSE:INO) from $1.50 to $2.50 in a research note issued to investors on Thursday, American Banking & Market News reports. The firm currently has a “hold” rating on the stock. Aegis’ price objective points to a potential upside of 12.11% from the company’s current price.

A number of other firms have also recently commented on INO. Analysts at Maxim Group raised their price target on shares of Inovio Pharmaceuticals (NYSE:INO) from $1.00 to $2.00 in a research note to investors on Tuesday, July 9th. They now have a “buy” rating on the stock. Analysts at Zacks downgraded shares of Inovio Pharmaceuticals (NYSE:INO) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, June 19th. They now have a $0.70 price target on the stock.